CytoDyn Inc., a late stage biotechnology company, is developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications and announced that the U.S. FDA has granted Fast Track Designation to leronlimab (PRO140) for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer (mTNBC).  Injection of the first patient in mTNBC is anticipated to be imminent.  Clinical trial sites include Quest Cli...